Wechselwirkungen · Abilify
ABILIFY 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 47
HOS-217856 · Präparat HOS-216111
Quinidine and other CYP2D6 inhibitors In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:00:00Z · SHA-256 48ec4699460ea38cacf1c891061adc75be0cb67e5657869eb4f756b4f121c005 · Passage 8dba665ffe6b64b523eb56cf6509b40990baa24dc052ded305a55b9ba925f661 · Zeichen 934–1546 im Abschnitt